GlassScriptPhysician profile
Samuel J Turner
NPI 1861678104
$60,182.82
in general payments reported to CMS, 2019-2025
32 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,655 · 2021: $2,065 · 2022: $2,145 · 2023: $1,634 · 2024: $31K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,750 · Food and Beverage: $6,321 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500 · Travel and Lodging: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,375.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,750.00 |
| Food and Beverage | $6,320.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
| Travel and Lodging | $1,902.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49,810.04 | 2019-2025 | Amplatzer Talisman, Jeti All In One Non-Sterile Kit, Triclip |
| Novartis Pharmaceuticals Corporation | $1,546.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,443.28 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Amgen INC. | $1,021.93 | 2019-2025 | Repatha |
| Abiomed | $816.78 | 2019-2025 | Impella |
| Boston Scientific Corporation | $740.11 | 2019-2025 | Watchman Access System, Farapulse, General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $729.32 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $721.11 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.90 | 2020-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.31 | 2019-2025 | Lifevest |
| Cvrx, INC. | $357.12 | 2022-2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $276.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $196.95 | 2021-2022 | |
| Vital Connect, INC | $153.72 | 2023-2025 | Vitalpatch Rtm |
| Atricure, INC. | $150.41 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $149.12 | 2024 | (Ck4) Mcot |
| Cardiva Medical, INC. | $144.07 | 2021-2025 | Optowire |
| Acist Medical Systems, INC. | $128.04 | 2024-2025 | |
| Biosense Webster, INC. | $127.43 | 2022-2025 | Nuvision Ice Catheter, Qdot Micro, Carto 3 |
| Pfizer INC. | $107.39 | 2020-2024 | |
| Inari Medical, INC. | $100.40 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $70.73 | 2019 | |
| Medtronic, INC. | $68.42 | 2023-2025 | Micra, Symplicity G3 |
| Bayer Healthcare Pharmaceuticals INC. | $65.82 | 2022-2023 | |
| Novo Nordisk INC | $53.32 | 2023-2024 | Rybelsus, Ozempic |
| Medtronic Vascular, INC. | $41.61 | 2019 | |
| Chiesi USA, INC. | $35.68 | 2024-2025 | Kengreal |
| Heartflow, INC. | $34.32 | 2025 | |
| Bridgebio Pharma, INC. | $31.49 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $29.27 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $19.99 | 2025 | Artis Pheno |
| Alnylam Pharmaceuticals INC. | $16.04 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.